«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 19

Page:

3801-3808

Research Field:

Publishing date:

Info

Title:

Research progress on the correlation between EGFR gene status and the efficacy of anti-angiogenic therapy in advanced non-small cell lung cancer

Author(s):

SHI Mengnan; HUANG Fang; JIANG Da

Department of Oncology,the Fourth Hospital of Hebei Medical University£¬Hebei Shijiazhuang 050011,China.

Keywords:

antivascular therapy; lung cancer; EGFR; VEGFR

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2024.19.031

Abstract:

Lung cancer is the most deadly malignant tumor in the world.In order to improve the overall therapeutic effect,anti-angiogenesis therapy has become an important part of the treatment of advanced non-small cell lung cancer(NSCLC).In addition,some studies have found that there is a certain relationship between the efficacy of these drugs and the gene status of epidermal growth factor receptor(EGFR) gene.These findings suggest that the dual blockade of vascular endothelial growth factor receptor(VEGFR) and EGFR may be a new option for NSCLC.Based on the development status of a number of anti-angiogenic drugs in the treatment of advanced NSCLC at home and abroad,this paper reviewed the correlation between EGFR gene status and efficacy of different anti-angiogenic drugs,and efficacy of anti-angiogenic drugs combined with EGFR tyrosine kinase inhibitors(TKI) in patients with EGFR mutations and special site metastasis,at the same time,the possible new mode of combined anti-angiogenic drugs in the treatment of NSCLC was prospected.

References:

£Û1£ÝTHAI AA,SOLOMON BJ,SEQUIST LV,et al.Lung cancer£ÛJ£Ý.Lancet,2021,398(10299):535-554.
£Û2£ÝNILSSON MB,ROBICHAUX J,HERYNK MH,et al.Altered regulation of HIF-1alpha in naive-and drug-resistant EGFR-mutant NSCLC:Implications for a vascular endothelial growth factor-dependent phenotype£ÛJ£Ý.J Thorac Oncol,2021,16(3):439-451.
£Û3£ÝGARCIA J,HURWITZ HI,SANDLER AB,et al.Bevacizumab(Avastin¡j) in cancer treatment:A review of 15 years of clinical experience and future outlook£ÛJ£Ý.Cancer Treat Rev,2020,86:102017.
£Û4£ÝZHOU C,WU YL,CHEN G,et al.BEYOND:A randomized,double-blind,placebo-controlled,multicenter,phase ¢ó study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer£ÛJ£Ý.J Clin Oncol,2015,33(19):2197-2204.
£Û5£ÝÖ£¾²æµ£¬Õž§£¬ÁÖ¾§£¬µÈ.±´·¥Öéµ¥¿¹ÁªºÏ»¯ÁÆÖÎÁƸ´ÖÎÍíÆÚ·ÇÁÛ·ÇСϸ°û·Î°©µÄÁÆЧ¼°°²È«ÐÔ¹Û²ì£ÛJ£Ý.ÁÙ´²Ö×ÁöѧÔÓÖ¾,2015,20(7):633-636. ZHENG JX,ZHANG J,LIN J,et al.Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of retreated advanced non-squamous non-small cell lung cancer£ÛJ£Ý.Journal of Clinical Oncology,2015,20(7):633-636.
£Û6£ÝSETO T,KATO T,NISHIO M,et al.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations(JO25567):An open-label,randomised,multicentre,phase 2 study£ÛJ£Ý.Lancet Oncol,2014,15(11):1236-1244.
£Û7£ÝSAITO H,FUKUHARA T,FURUYA N,et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer(NEJ026):Interim analysis of an open-label,randomised,multicentre,phase 3 trial£ÛJ£Ý.Lancet Oncol,2019,20(5):625-635.
£Û8£ÝZHOU Q,XU CR,CHENG Y,et al.Bevacizumab plus erlotinib in Chinese patients with untreated,EGFR-mutated,advanced NSCLC(ARTEMIS-CTONG1509):A multicenter phase 3 study£ÛJ£Ý.Cancer Cell,2021,39(9):1279-1291.
£Û9£ÝHERBST RS,ANSARI R,BUSTIN F,et al.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy(BeTa):A double-blind,placebo-controlled,phase 3 trial£ÛJ£Ý.Lancet,2011,377(9780):1846-1854.
£Û10£ÝSOO RA,HAN JY,DAFNI U,et al.A randomised phase ¢ò study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations:the European Thoracic Oncology Platform(ETOP 10-16) BOOSTER trial£ÛJ£Ý.Ann Oncol,2022,33(2):181-192.
£Û11£ÝKENMOTSU H,WAKUDA K,MORI K,et al.Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations:WJOG9717L study£ÛJ£Ý.J Thorac Oncol,2022,17(9):1098-1108.
£Û12£ÝZHOU G,GUO L,XU J,et al.Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations:A systematic review and Meta-analysis£ÛJ£Ý.Ther Adv Med Oncol,2024,16:17588359241227677.
£Û13£ÝJIANG Z,ZHANG J,SUN H,et al.Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations:A retrospective study£ÛJ£Ý.Thorac Cancer,2021,12(17):2369-2374.
£Û14£ÝYAMAMOTO N,SETO T,NISHIO M,et al.Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer:Survival follow-up results of the randomized JO25567 study£ÛJ£Ý.Lung Cancer,2021,151:20-24.
£Û15£ÝPICCIRILLO MC,BONANNO L,GARASSINO MC,et al.Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC:The BEVERLY multicenter randomized phase 3 trial£ÛJ£Ý.J Thorac Oncol,2022,17(9):1086-1097.
£Û16£ÝZHANG L,YOU Y,LIU X,et al.Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations£ÛJ£Ý.Thorac Cancer,2023,14(15):1355-1361.
£Û17£ÝBATY F,ROTHSCHILD S,FRUH M,et al.EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer£ÛJ£Ý.PLoS One,2013,8(9):e72966.
£Û18£ÝTAMIYA M,KUNIMASA K,NISHINO K,et al.Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation(G719S) with afatinib plus bevacizumab£ÛJ£Ý.Invest New Drugs,2021,39(1):232-236.
£Û19£ÝZHI X,LUO J,LI W,et al.Case report:Osimertinib followed by osimertinib plus bevacizumab,personalized treatment strategy for a lung cancer patient with a novel EGFR Exon 20 insertion D770_N771insGT and multiple brain metastases£ÛJ£Ý.Front Oncol,2021,11:733276.
£Û20£ÝZHANG L,SUN L,MU XY,et al.Bevacizumab combined with icotinib overcomes osimertinib resistance in a patient of non-small cell lung cancer£ÛJ£Ý.Chin Med Sci J,2019,34(4):292-296.
£Û21£ÝLIU S,PAN T,WANA MK,et al.Combination of bevacizumab and osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer£ÛJ£Ý.Clin Drug Investig,2022,42(5):459-464.
£Û22£ÝYANG X,MENG F,ZHONG D.Initial treatment of aumolertinib in combination with bevacizumab for advanced NSCLC with primary EGFR T790M mutation:A report of three cases and literature review£ÛJ£Ý.Chinese Journal of Lung Cancer,2023,26(2):158-164.
£Û23£ÝFURUGAKI K,FUKUMURA J,IWAI T,et al.Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification£ÛJ£Ý.Int J Cancer,2016,138(4):1024-1032.
£Û24£ÝROSELL R,DAFNI U,FELIP E,et al.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations(BELIEF):An international,multicentre,single-arm,phase 2 trial£ÛJ£Ý.Lancet Respir Med,2017,5(5):435-444.
£Û25£ÝCHEN S,XIANG T,LU W,et al.Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification:A case report£ÛJ£Ý.Medicine(Baltimore),2021,100(8):e24380.
£Û26£ÝSEKI N,NATSUME M,OCHIAI R,et al.Promising combination therapy with bevacizumab and erlotinib in an EGFR-mutated NSCLC patient with MET amplification who showed intrinsic resistance to initial EGFR-TKI therapy£ÛJ£Ý.Case Rep Oncol,2019,12(1):91-97.
£Û27£ÝCHENG Y,MA L,LIU Y,et al.Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors£ÛJ£Ý.Lung Cancer,2020,145:63-70.
£Û28£ÝZHANG Y,ZENG L,ZHANG X,et al.Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor(TKI) in EGFR-mutant advanced NSCLC£ÛJ£Ý.BMC Med,2021,19(1):245.
£Û29£ÝPAO W,WANG TY,RIELY GJ,et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib£ÛJ£Ý.PLoS Med,2005,2(1):e17.
£Û30£ÝNAUMOV GN,NILSSON MB,CASCONE T,et al.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor(EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance£ÛJ£Ý.Clin Cancer Res,2009,15(10):3484-3494.
£Û31£ÝYOH K,HOSOMI Y,KASAHARA K,et al.A randomized,double-blind,phase ¢ò study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage ¢ô non-small cell lung cancer after disease progression on platinum-based therapy£ÛJ£Ý.Lung Cancer,2016,99:186-193.
£Û32£ÝNAKAGAWA K,GARON EB,SETO T,et al.Ramucirumab plus erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer(RELAY):A randomised,double-blind,placebo-controlled,phase 3 trial£ÛJ£Ý.Lancet Oncol,2019,20(12):1655-1669.
£Û33£ÝNAKAGAWA K,NADAL E,GARON EB,et al.RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer£ÛJ£Ý.Clin Cancer Res,2021,27(19):5258-5271.
£Û34£ÝNISHIO M,PAZ-ARES L,RECK M,et al.RELAY,ramucirumab plus erlotinib(RAM+ERL) in untreated metastatic EGFR-mutant NSCLC(EGFR+NSCLC):Association between TP53 status and clinical outcome£ÛJ£Ý.Clin Lung Cancer,2023,24(5):415-428.
£Û35£ÝNISHINO K,SHIH JY,NAKAGAWA K,et al.RELAY,erlotinib plus ramucirumab in untreated,EGFR-mutated,metastatic NSCLC:Outcomes by EGFR Exon 19 deletion variants£ÛJ£Ý.JTO Clin Res Rep,2024,5(2):100624.
£Û36£ÝHUANG CY,HUANG HL,LAN CC,et al.A real-world study of Afatinib plus ramucirumab in treatment-naive,EGFR-mutated,non-small cell lung cancer£ÛJ£Ý.BMC Cancer,2023,23(1):413.
£Û37£ÝYU HA,PAZ-ARES LG,YANG JC,et al.Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer£ÛJ£Ý.Clin Cancer Res,2021,27(4):992-1002.
£Û38£ÝHONG SH,AN HJ,KIM K,et al.Impact of epidermal growth factor receptor mutation on clinical outcomes of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer from the Korean named patient program£ÛJ£Ý.Oncology,2019,96(1):51-58.
£Û39£ÝRIUDAVETS M,BOSCH-BARRERA J,CABEZON-GUTIERREZ L,et al.Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma£ÛJ£Ý.Clin Transl Oncol,2021,23(12):2560-2567.
£Û40£ÝSCAGLIOTTI GV,KRZAKOWSKI M,SZCZESNA A,et al.Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer:A phase ¢ó trial£ÛJ£Ý.J Clin Oncol,2012,30(17):2070-2078.
£Û41£ÝLU S,CHANG J,LIU X,et al.Randomized,double-blind,placebo-controlled,multicenter phase ¢ò study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer£ÛJ£Ý.J Clin Oncol,2018,36(12):1207-1217.
£Û42£ÝLU S,ZHOU JY,NIU XM,et al.Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer:A single-arm,phase ¢ò study£ÛJ£Ý.Transl Lung Cancer Res,2021,10(2):839-854.
£Û43£ÝWANG L,HE Z,YANG S,et al.The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer(NSCLC):A subgroup analysis of ALTER0303 trial£ÛJ£Ý.Transl Lung Cancer Res,2019,8(5):575-583.
£Û44£ÝLU J,ZHONG H,CHU T,et al.Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy£ÛJ£Ý.Eur Respir J,2019,53(3):1801562.
£Û45£ÝZHONG Q,LIU Z.Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer:A real-world study£ÛJ£Ý.Cancer Manag Res,2021,13:4115-4128.
£Û46£ÝLEI T,XU T,ZHANG N,et al.Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis£ÛJ£Ý.Pharmacol Res,2023,188:106668.
£Û47£ÝHAN R,GUO H,SHI J,et al.Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer£ÛJ£Ý.BMC Med,2024,22(1):174.
£Û48£ÝXIANG H,DANNA D,XUEFEI C,et al.The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer£ÛJ£Ý.Anticancer Drugs,2024,35(5):433-439.
£Û49£ÝZHAO H,YAO W,MIN X,et al.Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC:The phase ¢ó ACTIVE study(CTONG1706)£ÛJ£Ý.J Thorac Oncol,2021,16(9):1533-1546.
£Û50£ÝLIU M,LI X,ZHANG H,et al.Apatinib added when NSCLC patients get slow progression with EGFR-TKI:A prospective,single-arm study£ÛJ£Ý.Cancer Med,2023,12(24):21735-21741.
£Û51£ÝRANGACHARI D,YAMAGUCHI N,VANDERLAAN PA,et al.Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers£ÛJ£Ý.Lung Cancer,2015,88(1):108-111.
£Û52£ÝFENG PH,CHEN KY,HUANG YC,et al.Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma£ÛJ£Ý.J Thorac Oncol,2018,13(7):958-967.
£Û53£ÝJIANG T,ZHANG Y,LI X,et al.EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases£ÛJ£Ý.Eur J Cancer,2019,121:98-108.
£Û54£ÝWANG H,XING R,LI M,et al.The efficacy and clinical survival outcome of different first-line treatments in EGFR mutant non-small cell lung cancer with brain metastases£ÛJ£Ý.Journal of Thoracic Oncology,2021,16(10S):S1109.
£Û55£ÝXU J,LIU X,YANG S,et al.Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases£ÛJ£Ý.Oncol Res,2020,28(2):127-133.
£Û56£ÝALEXANDER M,LIN E,CHENG H.Leptomeningeal metastases in non-small cell lung cancer:Optimal systemic management in NSCLC with and without driver mutations£ÛJ£Ý.Curr Treat Options Oncol,2020,21(9):72.
£Û57£ÝJIANG T,XU X,CHEN X,et al.Osimertinib in combination with bevacizumab in EGFR-mutated NSCLC with leptomeningeal metastases£ÛJ£Ý.Transl Lung Cancer Res,2020,9(6):2514-2517.
£Û58£ÝTENG CK,CHEN CL,CHEN TH,et al.Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma:A report of two cases£ÛJ£Ý.Thorac Cancer,2022,13(9):1427-1430.
£Û59£ÝCEDILLO JL,BORDAS A,ARNALICH F,et al.Anti-tumoral activity of the human-specific duplicated form of alpha7-nicotinic receptor subunit in tobacco-induced lung cancer progression£ÛJ£Ý.Lung Cancer,2019,128:134-144.
£Û60£ÝPATEL SA,HERYNK MH,CASCONE T,et al.Estrogen promotes resistance to bevacizumab in murine models of NSCLC£ÛJ£Ý.J Thorac Oncol,2021,16(12):2051-2064.

Memo

Memo:

ºÓ±±Ê¡ÎÀÉú½¡¿µÎ¯Õþ¸®×ÊÖúÁÙ´²Ò½Ñ§ÓÅÐãÈ˲ÅÅàÑøÏîÄ¿£¨±àºÅ£º¼½²ÆÉ硲2019¡³139ºÅ£©

Common functions

Last Update: 2024-08-30